首页 > 最新文献

Drug, Healthcare and Patient Safety最新文献

英文 中文
Comparative Analysis of Adverse Drug Reactions Associated with Fluoroquinolones and Other Antibiotics: A Retrospective Pharmacovigilance Study.
IF 2.2 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-02-05 eCollection Date: 2025-01-01 DOI: 10.2147/DHPS.S497112
Hanan Alshareef, Khalidah A Alenzi, Budor R Albalawi, Rinas M Alanazi, Nawal S Albalawi, Wedad Saleem Alasoufi, Saleh Alqifari, Rehab Ahmed, Mostafa A S Ali

Background: Fluoroquinolones (FQs) are among the most popular antimicrobials that are highly effective against various infections. Although FQs are the most frequently used and generally tolerated, there are issues with their safety. This study assessed the rate, severity, seriousness, outcomes, and types of FQs adverse drug reactions (ADRs) in reports submitted to a regional spontaneous ADR database.

Methods: This was a retrospective cross-sectional observational study involving all patients with reported ADRs related to FQs or other antibiotics (ABs) that were submitted to the Regional Pharmacovigilance Center (PVC) database between January 2019 and December 2022. Data were extracted in the form of Saudi ADR from the PVC database, which is consistent with the MedWatch ADR form of the U.S Food and Drug Authority (FDA).

Results: In total, 605 ADRs related to antibiotic use were reported. ADRs caused by FQs use were the most frequently reported (177; 29.3%), followed by penicillin (100; 23.4%) and cephalosporin (90; 21%). There was no significant difference in ADRs caused by FQs between men (104; 58%) and women (OR 1.17, 95% CI 0.82-1.67, p=0.386). FQ-related ADRs were more frequent among those over 40 years-old (OR 1.56, 95% CI 1.09-2.22, p=0.015). Most of the detected FQ-related ADRs were of moderate severity (157; 88.7%), required interventions (83; 46.9%), and recovered after receiving medical interventions (154; 87%). Patients who received FQs were fourfold more likely to experience neurological adverse events (OR 4.15, 95% CI 2.48-6.93, p <0.001).

Conclusion: The FQs drug class exhibited a higher incidence of ADRs than other ABs. Regularly assessing the safety of ABs is crucial to improve public and healthcare providers' awareness of the correct utilization of ABs and to limit the use of FQs to infections that cannot be effectively managed with alternative ABs.

{"title":"Comparative Analysis of Adverse Drug Reactions Associated with Fluoroquinolones and Other Antibiotics: A Retrospective Pharmacovigilance Study.","authors":"Hanan Alshareef, Khalidah A Alenzi, Budor R Albalawi, Rinas M Alanazi, Nawal S Albalawi, Wedad Saleem Alasoufi, Saleh Alqifari, Rehab Ahmed, Mostafa A S Ali","doi":"10.2147/DHPS.S497112","DOIUrl":"10.2147/DHPS.S497112","url":null,"abstract":"<p><strong>Background: </strong>Fluoroquinolones (FQs) are among the most popular antimicrobials that are highly effective against various infections. Although FQs are the most frequently used and generally tolerated, there are issues with their safety. This study assessed the rate, severity, seriousness, outcomes, and types of FQs adverse drug reactions (ADRs) in reports submitted to a regional spontaneous ADR database.</p><p><strong>Methods: </strong>This was a retrospective cross-sectional observational study involving all patients with reported ADRs related to FQs or other antibiotics (ABs) that were submitted to the Regional Pharmacovigilance Center (PVC) database between January 2019 and December 2022. Data were extracted in the form of Saudi ADR from the PVC database, which is consistent with the MedWatch ADR form of the U.S Food and Drug Authority (FDA).</p><p><strong>Results: </strong>In total, 605 ADRs related to antibiotic use were reported. ADRs caused by FQs use were the most frequently reported (177; 29.3%), followed by penicillin (100; 23.4%) and cephalosporin (90; 21%). There was no significant difference in ADRs caused by FQs between men (104; 58%) and women (OR 1.17, 95% CI 0.82-1.67, p=0.386). FQ-related ADRs were more frequent among those over 40 years-old (OR 1.56, 95% CI 1.09-2.22, p=0.015). Most of the detected FQ-related ADRs were of moderate severity (157; 88.7%), required interventions (83; 46.9%), and recovered after receiving medical interventions (154; 87%). Patients who received FQs were fourfold more likely to experience neurological adverse events (OR 4.15, 95% CI 2.48-6.93, p <0.001).</p><p><strong>Conclusion: </strong>The FQs drug class exhibited a higher incidence of ADRs than other ABs. Regularly assessing the safety of ABs is crucial to improve public and healthcare providers' awareness of the correct utilization of ABs and to limit the use of FQs to infections that cannot be effectively managed with alternative ABs.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"17 ","pages":"51-62"},"PeriodicalIF":2.2,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Real-World Evidence to Assess Effectiveness Outcomes of Janus Kinase Inhibitors for Rheumatoid Arthritis: A Systematic Review of US Studies. 评估Janus激酶抑制剂治疗类风湿关节炎疗效的真实世界证据:美国研究的系统回顾
IF 2.2 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-01-07 eCollection Date: 2025-01-01 DOI: 10.2147/DHPS.S492887
Chandler Gandy, Shadi Bazzazzadehgan, Sebastian Bruera, Yinan Huang

Objective: This review summarized the real-world effectiveness outcomes of Janus kinase inhibitors (JAKi) for rheumatoid arthritis (RA) based on observational studies.

Methods: A systematic review followed PRISMA guidelines, with searches conducted in PubMed, Embase, and CINAHL from each database's inception to June 2, 2023. Studies were included if they evaluated real-world effectiveness outcomes of JAKi for US RA patients. Search terms included "RA", "JAKi", and "real-world". All citations were imported into COVIDENCE platform. Two reviewers independently performed title/abstract screening and full-text eligibility. For each article, study characteristics and effectiveness measures focusing on treatment pattern, clinical response, and patient-reported outcomes (PROs) of JAKi were extracted. Newcastle-Ottawa Scale (NOS) was utilized to assess the quality of the included articles.

Results: In total, 35 studies representing 252-30,556 patients were included. A majority used the administrative claims datasets (n=23, 65.71%), followed by 9 studies using electronic medical record (EMR) data and 3 studies using patient registry databases. Across claims-based studies, adherence, persistence, and effectiveness of JAKi were common outcomes. Adherence rates varied, with a proportion of days covered (PDC) ranging from 0.53 to 0.83 across 11 studies. Persistence of JAKi in RA patients was reported in 14 studies, where the median persistence time in treatment was reported to be between 121-516 days. Six studies applied effectiveness algorithms, with 14.8-26% of patients meeting effective treatment criteria. In addition, the most common measure of clinical response throughout the studies was Clinical Disease Activity Index (CDAI), with 10 articles reporting mean CDAI changes between -4.7 and 5.1. Across 12 studies that measured the PROs, the most prevalent PRO was pain, with the mean change in pain ranging from -9.3 to 8.9 across these studies.

Conclusion: Real-world studies on JAKi for RA reflect a range of effectiveness measures, illustrating the expanding role of JAKi in clinical practice.

目的:本综述根据观察性研究总结了类风湿关节炎(RA)患者使用 Janus 激酶抑制剂(JAKi)的实际疗效:本综述基于观察性研究总结了类风湿关节炎(RA)的 Janus 激酶抑制剂(JAKi)的实际疗效:系统性综述遵循PRISMA指南,在PubMed、Embase和CINAHL中进行了检索,检索时间从各数据库建立之初至2023年6月2日。对美国RA患者使用JAKi的实际疗效进行评估的研究均被纳入。检索词包括 "RA"、"JAKi "和 "真实世界"。所有引文均导入 COVIDENCE 平台。两名审稿人独立进行标题/摘要筛选和全文资格审查。对每篇文章的研究特点和有效性指标进行了提取,重点关注JAKi的治疗模式、临床反应和患者报告结果(PROs)。采用纽卡斯尔-渥太华量表(NOS)评估纳入文章的质量:共纳入35项研究,代表252-30556名患者。大多数研究使用了行政报销数据集(23 项,占 65.71%),9 项研究使用了电子病历数据,3 项研究使用了患者登记数据库。在基于索赔的研究中,JAKi的依从性、持续性和有效性是常见的结果。依从率各不相同,11项研究中的覆盖天数比例(PDC)从0.53到0.83不等。14项研究报告了JAKi在RA患者中的持续治疗情况,中位持续治疗时间介于121-516天之间。六项研究采用了疗效算法,14.8%-26%的患者符合有效治疗标准。此外,临床疾病活动指数(CDAI)是所有研究中最常用的临床反应测量指标,有10篇文章报道了CDAI的平均变化介于-4.7和5.1之间。在12项测量PRO的研究中,最常见的PRO是疼痛,这些研究中疼痛的平均变化范围在-9.3到8.9之间:结论:有关JAKi治疗RA的真实世界研究反映了一系列有效性指标,说明JAKi在临床实践中的作用正在不断扩大。
{"title":"Evaluation of Real-World Evidence to Assess Effectiveness Outcomes of Janus Kinase Inhibitors for Rheumatoid Arthritis: A Systematic Review of US Studies.","authors":"Chandler Gandy, Shadi Bazzazzadehgan, Sebastian Bruera, Yinan Huang","doi":"10.2147/DHPS.S492887","DOIUrl":"10.2147/DHPS.S492887","url":null,"abstract":"<p><strong>Objective: </strong>This review summarized the real-world effectiveness outcomes of Janus kinase inhibitors (JAKi) for rheumatoid arthritis (RA) based on observational studies.</p><p><strong>Methods: </strong>A systematic review followed PRISMA guidelines, with searches conducted in PubMed, Embase, and CINAHL from each database's inception to June 2, 2023. Studies were included if they evaluated real-world effectiveness outcomes of JAKi for US RA patients. Search terms included \"RA\", \"JAKi\", and \"real-world\". All citations were imported into COVIDENCE platform. Two reviewers independently performed title/abstract screening and full-text eligibility. For each article, study characteristics and effectiveness measures focusing on treatment pattern, clinical response, and patient-reported outcomes (PROs) of JAKi were extracted. Newcastle-Ottawa Scale (NOS) was utilized to assess the quality of the included articles.</p><p><strong>Results: </strong>In total, 35 studies representing 252-30,556 patients were included. A majority used the administrative claims datasets (n=23, 65.71%), followed by 9 studies using electronic medical record (EMR) data and 3 studies using patient registry databases. Across claims-based studies, adherence, persistence, and effectiveness of JAKi were common outcomes. Adherence rates varied, with a proportion of days covered (PDC) ranging from 0.53 to 0.83 across 11 studies. Persistence of JAKi in RA patients was reported in 14 studies, where the median persistence time in treatment was reported to be between 121-516 days. Six studies applied effectiveness algorithms, with 14.8-26% of patients meeting effective treatment criteria. In addition, the most common measure of clinical response throughout the studies was Clinical Disease Activity Index (CDAI), with 10 articles reporting mean CDAI changes between -4.7 and 5.1. Across 12 studies that measured the PROs, the most prevalent PRO was pain, with the mean change in pain ranging from -9.3 to 8.9 across these studies.</p><p><strong>Conclusion: </strong>Real-world studies on JAKi for RA reflect a range of effectiveness measures, illustrating the expanding role of JAKi in clinical practice.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"17 ","pages":"25-49"},"PeriodicalIF":2.2,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge, Attitude, and Practice Towards Responsible Self-Medication Among Pharmacy Students: A Web-Based Cross-Sectional Survey in Uganda. 药学专业学生对负责任的自我用药的知识、态度和实践:乌干达一项基于网络的横断面调查。
IF 2.2 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-01-07 eCollection Date: 2025-01-01 DOI: 10.2147/DHPS.S496924
Bukoli Brian, Narayana Goruntla, Bhavana Reddy Bommireddy, Bhavani M Mopuri, Vigneshwaran Easwaran, Mohammad Jaffar Sadiq Mantargi, Durga Prasad Thammisetty, Sarad Pawar Naik Bukke, Tadele Mekuriya Yadesa, Ebere Emilia Ayogu

Purpose: Rational self-medication (SM) practice among healthcare students is essential to promote the safe, effective, and economical use of medicines for self-diagnosed conditions. The study aimed to assess pharmacy students' knowledge, attitude, and practice about responsible self-medication.

Methodology: A cross-sectional online survey was conducted among Ugandan pharmacy students for one month from March 1 to March 31, 2024. The study included students enrolled in diploma, bachelor, and master of pharmacy programs in Uganda. Informed consent was obtained online by asking a question regarding willingness to participate. A non-probable snowball sampling technique was used to recruit students. A pre-validated questionnaire was used to obtain socio-demographics, self-medication practices, knowledge, attitudes, and practices about responsible self-medication. We used binary and multivariable logistic regression analysis to identify the factors associated with KAP regarding responsible self-medication.

Results: The prevalence of self-medication practice among pharmacy students was 96.73%. The self-medication is most common in headache (78.97%), cold, and cough (79.91%) illnesses. Painkillers (90.19%) and antibiotics (53.97%) are the most common medicines used for self-medication. Most pharmacy students have good knowledge (87.38%) and a positive attitude (96.03%) toward responsible self-medication. However, only 27.34% of students practice rational self-medication. Participants' university and parents' professions were significantly associated with good knowledge of responsible self-medication. Whereas factors such as gender, residence, and type of illness were significantly associated with rational self-medication practice.

Conclusion: The prevalence of self-medication was high among pharmacy students in Uganda. Painkillers and antibiotics are the most preferred drugs for self-medication. About 87.38% of pharmacy students have good knowledge, and 96.03% have a positive attitude toward responsible self-medication. Rational self-medication practice was low among students. We recommended training sessions to enhance safe self-medication practices among pharmacy students.

目的:在卫生保健专业学生中,合理的自我药疗(SM)实践对于促进安全、有效和经济地使用自我诊断疾病的药物是必不可少的。本研究旨在评估药学院学生对负责任自我药疗的知识、态度及行为。方法:从2024年3月1日至3月31日,对乌干达药学专业学生进行了为期一个月的横断面在线调查。研究对象包括在乌干达攻读药学文凭、学士和硕士课程的学生。通过在线询问有关参与意愿的问题获得知情同意。采用非概率雪球抽样技术招收学生。采用一份预验证问卷,了解社会人口统计学、自我药疗实践、关于负责任的自我药疗的知识、态度和实践。我们使用二元和多变量逻辑回归分析来确定与负责任的自我药疗相关的KAP因素。结果:药学专业学生自我药疗实践率为96.73%。自我用药在头痛(78.97%)、感冒和咳嗽(79.91%)疾病中最为常见。止痛药(90.19%)和抗生素(53.97%)是最常用于自我药疗的药物。大多数药学专业学生对负责任的自我药疗有良好的认识(87.38%)和积极的态度(96.03%)。然而,只有27.34%的学生进行了合理的自我药疗。参与者的大学和父母的职业与负责任的自我药疗的良好知识显著相关。而性别、居住地和疾病类型等因素与合理的自我药疗实践显著相关。结论:乌干达药学专业学生自我药疗率较高。止痛药和抗生素是自我治疗的首选药物。约87.38%的药学专业学生有良好的知识,96.03%的学生对负责任的自我药疗持积极态度。学生合理的自我药疗实践较少。我们推荐培训课程,以加强药学学生的安全自我用药实践。
{"title":"Knowledge, Attitude, and Practice Towards Responsible Self-Medication Among Pharmacy Students: A Web-Based Cross-Sectional Survey in Uganda.","authors":"Bukoli Brian, Narayana Goruntla, Bhavana Reddy Bommireddy, Bhavani M Mopuri, Vigneshwaran Easwaran, Mohammad Jaffar Sadiq Mantargi, Durga Prasad Thammisetty, Sarad Pawar Naik Bukke, Tadele Mekuriya Yadesa, Ebere Emilia Ayogu","doi":"10.2147/DHPS.S496924","DOIUrl":"10.2147/DHPS.S496924","url":null,"abstract":"<p><strong>Purpose: </strong>Rational self-medication (SM) practice among healthcare students is essential to promote the safe, effective, and economical use of medicines for self-diagnosed conditions. The study aimed to assess pharmacy students' knowledge, attitude, and practice about responsible self-medication.</p><p><strong>Methodology: </strong>A cross-sectional online survey was conducted among Ugandan pharmacy students for one month from March 1 to March 31, 2024. The study included students enrolled in diploma, bachelor, and master of pharmacy programs in Uganda. Informed consent was obtained online by asking a question regarding willingness to participate. A non-probable snowball sampling technique was used to recruit students. A pre-validated questionnaire was used to obtain socio-demographics, self-medication practices, knowledge, attitudes, and practices about responsible self-medication. We used binary and multivariable logistic regression analysis to identify the factors associated with KAP regarding responsible self-medication.</p><p><strong>Results: </strong>The prevalence of self-medication practice among pharmacy students was 96.73%. The self-medication is most common in headache (78.97%), cold, and cough (79.91%) illnesses. Painkillers (90.19%) and antibiotics (53.97%) are the most common medicines used for self-medication. Most pharmacy students have good knowledge (87.38%) and a positive attitude (96.03%) toward responsible self-medication. However, only 27.34% of students practice rational self-medication. Participants' university and parents' professions were significantly associated with good knowledge of responsible self-medication. Whereas factors such as gender, residence, and type of illness were significantly associated with rational self-medication practice.</p><p><strong>Conclusion: </strong>The prevalence of self-medication was high among pharmacy students in Uganda. Painkillers and antibiotics are the most preferred drugs for self-medication. About 87.38% of pharmacy students have good knowledge, and 96.03% have a positive attitude toward responsible self-medication. Rational self-medication practice was low among students. We recommended training sessions to enhance safe self-medication practices among pharmacy students.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"17 ","pages":"7-23"},"PeriodicalIF":2.2,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute Niclofolan Intoxication Led to Stillbirth: A Case Report. 急性硝氯福兰中毒致死产1例报告。
IF 2.2 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-01-06 eCollection Date: 2025-01-01 DOI: 10.2147/DHPS.S491648
Rui Feng Li, Liang Fen Wang, Hai Ying Zhang, Meng Jie He

Niclofolan is a commonly used veterinary drug worldwide. We reported a case of acute niclofolan intoxication in a pregnant woman. We recorded in detail her toxic symptoms, including nausea, vomiting, asthenia, blurred vision, and aberrant blood values. Notably stillbirth was recorded for the first time as indicating its human reproductive toxicity. We also found that an oral therapeutic dosage as described in the literature was likely to lead to stillbirth. Furthermore, we described the treatments received by the patient, including critical care, drug therapy, and plasma exchange, the outcomes of which were excellent. By studying this case, we aimed to enhance recognition and treatment of niclofolan intoxication and to raise concern regarding veterinary drug abuse and exposure risk.

尼克洛福兰是世界范围内常用的兽药。我们报告了一例急性氯福兰中毒的孕妇。我们详细记录了她的中毒症状,包括恶心、呕吐、虚弱、视力模糊和血值异常。值得注意的是,死产首次被记录下来,表明其对人类生殖的毒性。我们还发现,文献中描述的口服治疗剂量可能导致死产。此外,我们描述了患者接受的治疗,包括重症监护、药物治疗和血浆交换,结果非常好。通过对该病例的研究,我们旨在提高对氯福兰中毒的认识和治疗,并提高对兽药滥用和暴露风险的关注。
{"title":"Acute Niclofolan Intoxication Led to Stillbirth: A Case Report.","authors":"Rui Feng Li, Liang Fen Wang, Hai Ying Zhang, Meng Jie He","doi":"10.2147/DHPS.S491648","DOIUrl":"10.2147/DHPS.S491648","url":null,"abstract":"<p><p>Niclofolan is a commonly used veterinary drug worldwide. We reported a case of acute niclofolan intoxication in a pregnant woman. We recorded in detail her toxic symptoms, including nausea, vomiting, asthenia, blurred vision, and aberrant blood values. Notably stillbirth was recorded for the first time as indicating its human reproductive toxicity. We also found that an oral therapeutic dosage as described in the literature was likely to lead to stillbirth. Furthermore, we described the treatments received by the patient, including critical care, drug therapy, and plasma exchange, the outcomes of which were excellent. By studying this case, we aimed to enhance recognition and treatment of niclofolan intoxication and to raise concern regarding veterinary drug abuse and exposure risk.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"17 ","pages":"1-6"},"PeriodicalIF":2.2,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Cross-Sectional Evaluation of Opioid Dispensing Competencies in Final-Year Pharm-D Students: A Multicenter Study from Punjab, Pakistan. 阿片类药物配药能力的横断面评估在最后一年药学d学生:多中心研究从旁遮普,巴基斯坦。
IF 2.2 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-12-28 eCollection Date: 2024-01-01 DOI: 10.2147/DHPS.S491717
Naeem Mubarak, Fatima Rahman Rana, Taheer Zahid, Umm-E-Barirah Ijaz, Afshan Shabbir, Ahtesham Ghulam Bari, Bisma Niaz, Sabba Kanwal, Nasira Saif-Ur-Rahman, Zahid Iqbal, Asad Majeed Khan, Che Suraya Zin, Khalid Mahmood, Mohamed Hassan Elnaem, Saba Tariq

Background: The opioid crisis continues to be a public health concern worldwide due to the high rates of misuse and associated mortality. Opioid dispensing competencies are critical for pharmacy graduates to promote the rational use of opioids.

Purpose: To evaluate the opioids dispensing competencies among the final year Pharm-D students in Punjab, Pakistan.

Design: A multicenter cross-sectional study.

Methods: A validated survey was used to evaluate 11 competencies related to opioid use from the final year Pharm-D students from diversely located accredited institutes. On a summative scale, correct response to each survey item was worth a score/point. Descriptive statistics was used for categorical variables while independent t-test computed group differences.

Results: A total of n = 661 final year Pharm-D students from 28 institutes (8 public and 20 private) completed the survey with an overall response rate of 78.5%. Comparatively, the students who had either completed a community or hospital internship, or studying in the educational institutions located in the provincial capital demonstrated a significant higher competency score. There was no significant difference in the overall mean competency scores based on gender or system of assessment used in the Pharm-D degree programs. Among eleven opioid competencies, students received the lowest scores for "opioid overdose management", "opioid monitoring" and "therapeutic uses of opioids".

Conclusion: Pharm-D students in Pakistan require additional training and skills on many of the opioids related competencies to ensure patient's safety in healthcare settings. There is a need to revise the curriculum and teaching methodologies to improve the competencies of Pharm-D students in opioid dispensing.

背景:由于阿片类药物的高滥用率和相关死亡率,阿片类药物危机一直是全球关注的公共卫生问题。目的:评估巴基斯坦旁遮普省药学博士毕业班学生的阿片类药物配制能力:设计:一项多中心横断面研究:方法:采用经过验证的调查方法,对来自不同地区经认证院校的药学博士研究生进行 11 项与阿片类药物使用相关的能力评估。在总结性量表中,对每个调查项目的正确回答得分为/分。对分类变量采用描述性统计,对组间差异采用独立 t 检验:共有来自 28 所院校(8 所公立院校和 20 所私立院校)的 661 名药学博士毕业班学生完成了调查,总回复率为 78.5%。相比之下,完成社区或医院实习或在省会教育机构学习的学生的能力得分明显较高。不同性别的学生和药学博士学位课程所使用的评估系统在总体平均能力得分上没有明显差异。在11项阿片类药物能力中,学生在 "阿片类药物过量管理"、"阿片类药物监测 "和 "阿片类药物的治疗用途 "方面得分最低:结论:巴基斯坦的药学博士生需要在许多阿片类药物相关能力方面接受更多培训并掌握更多技能,以确保医疗机构中患者的安全。有必要修订课程和教学方法,以提高药学博士生在阿片类药物配药方面的能力。
{"title":"A Cross-Sectional Evaluation of Opioid Dispensing Competencies in Final-Year Pharm-D Students: A Multicenter Study from Punjab, Pakistan.","authors":"Naeem Mubarak, Fatima Rahman Rana, Taheer Zahid, Umm-E-Barirah Ijaz, Afshan Shabbir, Ahtesham Ghulam Bari, Bisma Niaz, Sabba Kanwal, Nasira Saif-Ur-Rahman, Zahid Iqbal, Asad Majeed Khan, Che Suraya Zin, Khalid Mahmood, Mohamed Hassan Elnaem, Saba Tariq","doi":"10.2147/DHPS.S491717","DOIUrl":"10.2147/DHPS.S491717","url":null,"abstract":"<p><strong>Background: </strong>The opioid crisis continues to be a public health concern worldwide due to the high rates of misuse and associated mortality. Opioid dispensing competencies are critical for pharmacy graduates to promote the rational use of opioids.</p><p><strong>Purpose: </strong>To evaluate the opioids dispensing competencies among the final year Pharm-D students in Punjab, Pakistan.</p><p><strong>Design: </strong>A multicenter cross-sectional study.</p><p><strong>Methods: </strong>A validated survey was used to evaluate 11 competencies related to opioid use from the final year Pharm-D students from diversely located accredited institutes. On a summative scale, correct response to each survey item was worth a score/point. Descriptive statistics was used for categorical variables while independent <i>t</i>-test computed group differences.</p><p><strong>Results: </strong>A total of n = 661 final year Pharm-D students from 28 institutes (8 public and 20 private) completed the survey with an overall response rate of 78.5%. Comparatively, the students who had either completed a community or hospital internship, or studying in the educational institutions located in the provincial capital demonstrated a significant higher competency score. There was no significant difference in the overall mean competency scores based on gender or system of assessment used in the Pharm-D degree programs. Among eleven opioid competencies, students received the lowest scores for \"opioid overdose management\", \"opioid monitoring\" and \"therapeutic uses of opioids\".</p><p><strong>Conclusion: </strong>Pharm-D students in Pakistan require additional training and skills on many of the opioids related competencies to ensure patient's safety in healthcare settings. There is a need to revise the curriculum and teaching methodologies to improve the competencies of Pharm-D students in opioid dispensing.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"16 ","pages":"133-144"},"PeriodicalIF":2.2,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142920996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of Using Pharmacists as a Medication Safety Information Resource Among Women of Reproductive Age. 利用药师作为育龄妇女用药安全信息资源的预测因素。
IF 2.2 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-12-07 eCollection Date: 2024-01-01 DOI: 10.2147/DHPS.S412786
Mary K Awuonda, Ghada Alem, Brittany Olbert, Medha Reddy, Monika Daftary, La'Marcus Wingate, Earl Ettienne

Background: Medication use during pregnancy is prevalent with notable increases in the use of over-the-counter medications. In this era of information proliferation, it is important to understand where women of reproductive age obtain information on medication safety.

Objective: The main objective of this study was to determine the predictive factors associated with the utilization of pharmacists as a medication information safety resource among reproductive age women.

Methods: A cross-sectional evaluation of baseline characteristics, collected during an online knowledge intervention study, was conducted among women aged 18-44 who were living in the United States in 2018 to 2019. Descriptive statistics for all study variables were estimated. Logistic regression analyses were done to assess the predictors of the utilization of pharmacists as a medication safety resource.

Results: A total of 210 women of reproductive age were included in the study. The average age was 32.4 ± 6.5 years and the majority were White (69.5%), married (61.4%), and had at least a high school education level (86%). Fifty four percent of participants reported using pharmacists as a medication safety information resource. Findings from the multivariable analyses showed that women who reported difficulty understanding written medical information (p = 0.018) and those who were Black or African American (p = 0.008) had less odds of utilizing pharmacists as a medication information source.

Conclusion: Despite pharmacists being one of the most accessible health care professionals on medication information, only 54.3% of women surveyed utilized them as medication information sources. It was also found that women who had difficulty understanding written information and those who were Black or African American were less likely to utilize pharmacists as a medication safety information resource. Findings show opportunities for pharmacists to increase perceived value as medication safety experts among women of childbearing age. Additional studies need to be conducted given the study's limited generalizability.

背景:怀孕期间的药物使用很普遍,非处方药的使用明显增加。在这个信息泛滥的时代,了解育龄妇女从哪里获得药物安全信息是很重要的。目的:本研究的主要目的是确定育龄妇女利用药师作为用药信息安全资源的预测因素。方法:对2018年至2019年居住在美国的18-44岁女性进行基线特征的横断面评估,这些基线特征是在一项在线知识干预研究中收集的。对所有研究变量进行描述性统计。采用Logistic回归分析评估药师作为用药安全资源利用的预测因素。结果:共纳入210名育龄妇女。平均年龄32.4±6.5岁,白人(69.5%)、已婚(61.4%)、高中以上文化程度(86%)居多。54%的参与者报告使用药剂师作为药物安全信息资源。多变量分析的结果显示,报告难以理解书面医疗信息的妇女(p = 0.018)和黑人或非裔美国人(p = 0.008)利用药剂师作为药物信息源的几率较小。结论:尽管药剂师是最容易获得药物信息的卫生保健专业人员之一,但只有54.3%的受访妇女将其作为药物信息来源。研究还发现,理解书面信息有困难的妇女以及黑人或非裔美国人不太可能利用药剂师作为药物安全信息资源。研究结果表明,药剂师有机会增加作为育龄妇女用药安全专家的感知价值。鉴于该研究的推广能力有限,需要进行更多的研究。
{"title":"Predictors of Using Pharmacists as a Medication Safety Information Resource Among Women of Reproductive Age.","authors":"Mary K Awuonda, Ghada Alem, Brittany Olbert, Medha Reddy, Monika Daftary, La'Marcus Wingate, Earl Ettienne","doi":"10.2147/DHPS.S412786","DOIUrl":"10.2147/DHPS.S412786","url":null,"abstract":"<p><strong>Background: </strong>Medication use during pregnancy is prevalent with notable increases in the use of over-the-counter medications. In this era of information proliferation, it is important to understand where women of reproductive age obtain information on medication safety.</p><p><strong>Objective: </strong>The main objective of this study was to determine the predictive factors associated with the utilization of pharmacists as a medication information safety resource among reproductive age women.</p><p><strong>Methods: </strong>A cross-sectional evaluation of baseline characteristics, collected during an online knowledge intervention study, was conducted among women aged 18-44 who were living in the United States in 2018 to 2019. Descriptive statistics for all study variables were estimated. Logistic regression analyses were done to assess the predictors of the utilization of pharmacists as a medication safety resource.</p><p><strong>Results: </strong>A total of 210 women of reproductive age were included in the study. The average age was 32.4 ± 6.5 years and the majority were White (69.5%), married (61.4%), and had at least a high school education level (86%). Fifty four percent of participants reported using pharmacists as a medication safety information resource. Findings from the multivariable analyses showed that women who reported difficulty understanding written medical information (p = 0.018) and those who were Black or African American (p = 0.008) had less odds of utilizing pharmacists as a medication information source.</p><p><strong>Conclusion: </strong>Despite pharmacists being one of the most accessible health care professionals on medication information, only 54.3% of women surveyed utilized them as medication information sources. It was also found that women who had difficulty understanding written information and those who were Black or African American were less likely to utilize pharmacists as a medication safety information resource. Findings show opportunities for pharmacists to increase perceived value as medication safety experts among women of childbearing age. Additional studies need to be conducted given the study's limited generalizability.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"16 ","pages":"125-132"},"PeriodicalIF":2.2,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Sacubitril/Valsartan on Heart Failure Patient with Reduced Left Ventricular Ejection Fraction: Single Center Retrospective Study in Saudi Arabia. 沙奎利/缬沙坦对左心室射血分数降低的心衰患者的影响:沙特阿拉伯单中心回顾性研究。
IF 2.2 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.2147/DHPS.S471867
Sultan Al Raddadi, Majed Almutairi, Kholoud AlAamer, Abdulmahsen Alsalman, Maram Albalawi, Meshary Almeshary, Hisham A Badreldin, Hind Almodaimegh

Background: Sacubitril/valsartan (S/V) is used in managing heart failure with reduced ejection fraction (HFrEF), reducing morbidity and mortality while improving symptoms and prognosis. This study aims to evaluate the effectiveness of S/V in patients with reduced left ventricular ejection fraction (LVEF) and its safety.

Methods:  This retrospective cohort study included adult patients aged ≥18 years diagnosed with HFrEF, receiving S/V, and followed up at a tertiary hospital in Riyadh. Primary outcomes included improvements in LVEF on echocardiography and the number of hospitalizations due to acute decompensated heart failure (ADHF). Secondary outcomes assessed the safety profile of S/V. Multinomial logistic regression analysis was performed with statistical significance set at P < 0.05. .

Results: The study included 107 patients: 80 with LVEF < 30% and 27 with LVEF 30-40%. Six-month follow-up, LVEF improvement was categorized into three groups: no improvement, LVEF increased by 1 to <10 points, and LVEF increased by ≥10 points. The LVEF was similar across groups (P = 0.59). Although hospitalizations due to ADHF were not significantly different between groups, they numerically decreased after initiating S/V (P = 0.1). S/V was generally well tolerated.

Conclusion: This study suggests no significant benefit from S/V regarding LVEF improvement. It is recommended that heart failure clinics assess and titrate S/V to the maximum tolerated dose.

背景:沙库比特利/缬沙坦(S/V)用于治疗射血分数降低的心力衰竭(HFrEF),可降低发病率和死亡率,同时改善症状和预后。本研究旨在评估S/V对左心室射血分数(LVEF)降低患者的有效性及其安全性:这项回顾性队列研究纳入了利雅得一家三级医院确诊为 HFrEF、接受 S/V 治疗并接受随访的年龄≥18 岁的成年患者。主要结果包括超声心动图显示的 LVEF 改善情况和因急性失代偿性心力衰竭 (ADHF) 而住院的人数。次要结果是评估 S/V 的安全性。进行了多项式逻辑回归分析,统计显著性设定为 P <0.05。.结果研究共纳入 107 名患者:80例患者 LVEF < 30%,27例患者 LVEF 30-40%。随访六个月后,LVEF改善情况分为三组:无改善、LVEF增加1至结论:本研究表明,S/V 对 LVEF 的改善无明显益处。建议心衰诊所对 S/V 进行评估,并将其剂量调整到最大耐受剂量。
{"title":"The Impact of Sacubitril/Valsartan on Heart Failure Patient with Reduced Left Ventricular Ejection Fraction: Single Center Retrospective Study in Saudi Arabia.","authors":"Sultan Al Raddadi, Majed Almutairi, Kholoud AlAamer, Abdulmahsen Alsalman, Maram Albalawi, Meshary Almeshary, Hisham A Badreldin, Hind Almodaimegh","doi":"10.2147/DHPS.S471867","DOIUrl":"10.2147/DHPS.S471867","url":null,"abstract":"<p><strong>Background: </strong>Sacubitril/valsartan (S/V) is used in managing heart failure with reduced ejection fraction (HFrEF), reducing morbidity and mortality while improving symptoms and prognosis. This study aims to evaluate the effectiveness of S/V in patients with reduced left ventricular ejection fraction (LVEF) and its safety.</p><p><strong>Methods: </strong> This retrospective cohort study included adult patients aged ≥18 years diagnosed with HFrEF, receiving S/V, and followed up at a tertiary hospital in Riyadh. Primary outcomes included improvements in LVEF on echocardiography and the number of hospitalizations due to acute decompensated heart failure (ADHF). Secondary outcomes assessed the safety profile of S/V. Multinomial logistic regression analysis was performed with statistical significance set at P < 0.05. .</p><p><strong>Results: </strong>The study included 107 patients: 80 with LVEF < 30% and 27 with LVEF 30-40%. Six-month follow-up, LVEF improvement was categorized into three groups: no improvement, LVEF increased by 1 to <10 points, and LVEF increased by ≥10 points. The LVEF was similar across groups (P = 0.59). Although hospitalizations due to ADHF were not significantly different between groups, they numerically decreased after initiating S/V (P = 0.1). S/V was generally well tolerated.</p><p><strong>Conclusion: </strong>This study suggests no significant benefit from S/V regarding LVEF improvement. It is recommended that heart failure clinics assess and titrate S/V to the maximum tolerated dose.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"16 ","pages":"117-124"},"PeriodicalIF":2.2,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11451457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse Events Following Immunization with Novel Oral Polio Vaccine Type 2, and the Experience and Challenges of Reporting in Sierra Leone [Response to Letter]. 新型口服脊髓灰质炎 2 型疫苗免疫接种后的不良事件,以及塞拉利昂在报告方面的经验和挑战[对信函的答复]。
IF 2.2 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-09-29 eCollection Date: 2024-01-01 DOI: 10.2147/DHPS.S496511
Fawzi Thomas, Onome T Abiri, Joyce M Kallon, Desmond Maada Kangbai, Thomas A Conteh, Sally-Mattu Conteh, Edna G Samuels, Olufunsho Awodele
{"title":"Adverse Events Following Immunization with Novel Oral Polio Vaccine Type 2, and the Experience and Challenges of Reporting in Sierra Leone [Response to Letter].","authors":"Fawzi Thomas, Onome T Abiri, Joyce M Kallon, Desmond Maada Kangbai, Thomas A Conteh, Sally-Mattu Conteh, Edna G Samuels, Olufunsho Awodele","doi":"10.2147/DHPS.S496511","DOIUrl":"10.2147/DHPS.S496511","url":null,"abstract":"","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"16 ","pages":"115-116"},"PeriodicalIF":2.2,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11448459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baloxavir Resistance Markers in Influenza A and B Viruses in the Americas. 美洲甲型和乙型流感病毒中的巴洛沙韦抗药性标记。
IF 2.2 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-09-14 eCollection Date: 2024-01-01 DOI: 10.2147/DHPS.S470868
Erick Acocal-Juárez, Luis Márquez-Domínguez, Verónica Vallejo-Ruíz, Lilia Cedillo, Gerardo Santos-López

Aim: Influenza control demands multifaceted strategies, including antiviral drugs. Baloxavir, a recent addition to influenza treatment, acts as an inhibitor of the Polymerase acid (PA) component of the viral polymerase. However, mutations associated with resistance have been identified.

Purpose: This study analyzed PA gene sequences of influenza A and B viruses (IAV and IBV, respectively) reported in the Americas, retrieved from databases published until May 2023, to identify primary markers of resistance to baloxavir.

Patients and methods: PA gene sequences were obtained from the GISAID and NCBI databases, focusing on countries in the Americas with 500 or more sequences for IAV, and 50 or more sequences for IBV.

Results: Of the 58,816 PA sequences analyzed for IAV, only 55 (0.1%) harbored resistance markers, representing approximately 1 in 1000 occurrence. The most frequent markers were I38V (21 cases) and I38M (7 cases) at position 38 of PA, followed by E199G (9 cases) at position 199. For IBV, 14,684 sequences were analyzed, of which only eight presented a resistance marker (0.05%). Five sequences had the M34I marker, while the remaining three had the I38V marker. While frequency of resistance markers in PA is comparable to other regions, these results highlight the need for enhanced sequencing efforts, particularly in Latin America. Such efforts would serve to intensify influenza surveillance and inform public health interventions.

Conclusion: While baloxavir demonstrates efficacy against influenza, resistance markers have been identified, including pre-existing ones. Our study adds eight (IAV: six and IBV: two) new spontaneously occurring substitutions to the existing literature, highlighting the need for continued surveillance. Among these, I38M stands out due to its significant tenfold reduction in drug susceptibility. Therefore, vigilant monitoring of these resistance markers in IAV and IBV remains crucial for maintaining baloxavir's effectiveness and informing future public health interventions.

目的:流感控制需要多方面的策略,包括抗病毒药物。巴洛沙韦是最近加入流感治疗的一种药物,它是病毒聚合酶酸(PA)成分的抑制剂。目的:本研究分析了美洲地区报道的甲型流感病毒和乙型流感病毒(分别为 IAV 和 IBV)的 PA 基因序列(检索自 2023 年 5 月之前发布的数据库),以确定对巴洛沙韦耐药性的主要标记物:从GISAID和NCBI数据库中获取PA基因序列,重点关注美洲国家中IAV和IBV的PA基因序列分别达到500个和50个以上的国家:结果:在分析的 58816 个 IAV PA 序列中,只有 55 个(0.1%)带有抗性标记,约为千分之一。最常见的标记是 PA 第 38 位的 I38V(21 例)和 I38M(7 例),其次是第 199 位的 E199G(9 例)。对于 IBV,分析了 14 684 个序列,其中只有 8 个序列出现抗性标记(0.05%)。其中 5 个序列具有 M34I 标记,其余 3 个序列具有 I38V 标记。虽然 PA 的抗药性标记频率与其他地区相当,但这些结果凸显了加强测序工作的必要性,尤其是在拉丁美洲。这些工作将有助于加强流感监测并为公共卫生干预措施提供信息:结论:虽然巴洛沙韦对流感有疗效,但耐药性标记物已经被发现,包括以前就存在的标记物。我们的研究为现有文献增添了八种(IAV:六种,IBV:两种)新的自发发生的替换,突出了持续监测的必要性。其中,I38M 因其药物敏感性显著降低十倍而脱颖而出。因此,对 IAV 和 IBV 中的这些耐药性标记进行警惕性监测对于保持巴洛沙韦的有效性和为未来的公共卫生干预措施提供信息仍然至关重要。
{"title":"Baloxavir Resistance Markers in Influenza A and B Viruses in the Americas.","authors":"Erick Acocal-Juárez, Luis Márquez-Domínguez, Verónica Vallejo-Ruíz, Lilia Cedillo, Gerardo Santos-López","doi":"10.2147/DHPS.S470868","DOIUrl":"https://doi.org/10.2147/DHPS.S470868","url":null,"abstract":"<p><strong>Aim: </strong>Influenza control demands multifaceted strategies, including antiviral drugs. Baloxavir, a recent addition to influenza treatment, acts as an inhibitor of the Polymerase acid (PA) component of the viral polymerase. However, mutations associated with resistance have been identified.</p><p><strong>Purpose: </strong>This study analyzed PA gene sequences of influenza A and B viruses (IAV and IBV, respectively) reported in the Americas, retrieved from databases published until May 2023, to identify primary markers of resistance to baloxavir.</p><p><strong>Patients and methods: </strong>PA gene sequences were obtained from the GISAID and NCBI databases, focusing on countries in the Americas with 500 or more sequences for IAV, and 50 or more sequences for IBV.</p><p><strong>Results: </strong>Of the 58,816 PA sequences analyzed for IAV, only 55 (0.1%) harbored resistance markers, representing approximately 1 in 1000 occurrence. The most frequent markers were I38V (21 cases) and I38M (7 cases) at position 38 of PA, followed by E199G (9 cases) at position 199. For IBV, 14,684 sequences were analyzed, of which only eight presented a resistance marker (0.05%). Five sequences had the M34I marker, while the remaining three had the I38V marker. While frequency of resistance markers in PA is comparable to other regions, these results highlight the need for enhanced sequencing efforts, particularly in Latin America. Such efforts would serve to intensify influenza surveillance and inform public health interventions.</p><p><strong>Conclusion: </strong>While baloxavir demonstrates efficacy against influenza, resistance markers have been identified, including pre-existing ones. Our study adds eight (IAV: six and IBV: two) new spontaneously occurring substitutions to the existing literature, highlighting the need for continued surveillance. Among these, I38M stands out due to its significant tenfold reduction in drug susceptibility. Therefore, vigilant monitoring of these resistance markers in IAV and IBV remains crucial for maintaining baloxavir's effectiveness and informing future public health interventions.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"16 ","pages":"105-113"},"PeriodicalIF":2.2,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11410037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse Events Following Immunization with Novel Oral Polio Vaccine Type 2, and the Experience and Challenges of Reporting in Sierra Leone [Letter]. 新型口服脊髓灰质炎 2 型疫苗免疫接种后出现的不良事件,以及塞拉利昂在报告方面的经验和挑战 [信函]。
IF 2.2 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-09-04 eCollection Date: 2024-01-01 DOI: 10.2147/DHPS.S487045
Nuril Endi Rahman
{"title":"Adverse Events Following Immunization with Novel Oral Polio Vaccine Type 2, and the Experience and Challenges of Reporting in Sierra Leone [Letter].","authors":"Nuril Endi Rahman","doi":"10.2147/DHPS.S487045","DOIUrl":"10.2147/DHPS.S487045","url":null,"abstract":"","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"16 ","pages":"103-104"},"PeriodicalIF":2.2,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142157162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Drug, Healthcare and Patient Safety
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1